Amneal Pharmaceuticals, Inc. (AMRX)
AMRX Stock Price Chart
Explore Amneal Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze AMRX price movements and trends.
AMRX Company Profile
Discover essential business fundamentals and corporate details for Amneal Pharmaceuticals, Inc. (AMRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
7 May 2018
Employees
8.30k
Website
https://www.amneal.comCEO
Chirag K. Patel
Description
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
AMRX Financial Timeline
Browse a chronological timeline of Amneal Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is $0.24, while revenue estimate is $768.21m.
Earnings released on 7 May 2026
EPS came in at $0.27 surpassing the estimated $0.17 by +58.82%, while revenue for the quarter reached $722.52m , beating expectations by +0.40%.
Earnings released on 27 Feb 2026
EPS came in at $0.21 surpassing the estimated $0.18 by +16.67%, while revenue for the quarter reached $814.32m , beating expectations by +0.86%.
Earnings released on 30 Oct 2025
EPS came in at $0.17 surpassing the estimated $0.13 by +30.77%, while revenue for the quarter reached $784.51m , missing expectations by -2.67%.
Earnings released on 5 Aug 2025
EPS came in at $0.25 surpassing the estimated $0.18 by +38.89%, while revenue for the quarter reached $724.51m , missing expectations by -5.74%.
Earnings released on 2 May 2025
EPS came in at $0.21 surpassing the estimated $0.15 by +40.00%, while revenue for the quarter reached $695.42m , missing expectations by -6.56%.
Earnings released on 28 Feb 2025
EPS came in at $0.12 falling short of the estimated $0.15 by -20.00%, while revenue for the quarter reached $730.52m , beating expectations by +1.03%.
Earnings released on 8 Nov 2024
EPS came in at $0.16 surpassing the estimated $0.13 by +23.08%, while revenue for the quarter reached $702.47m , beating expectations by +0.23%.
Earnings released on 9 Aug 2024
EPS came in at $0.16 surpassing the estimated $0.14 by +14.29%, while revenue for the quarter reached $701.78m , beating expectations by +6.63%.
Earnings released on 3 May 2024
EPS came in at $0.14 surpassing the estimated $0.09 by +55.56%, while revenue for the quarter reached $659.19m .
Earnings released on 1 Mar 2024
EPS came in at $0.14 surpassing the estimated $0.07 by +100.00%, while revenue for the quarter reached $616.98m , missing expectations by -7.02%.
Earnings released on 7 Nov 2023
EPS came in at $0.19 surpassing the estimated $0.12 by +58.33%, while revenue for the quarter reached $620.04m , missing expectations by -2.24%.
Earnings released on 4 Aug 2023
EPS came in at $0.19 surpassing the estimated $0.10 by +90.00%, while revenue for the quarter reached $599.05m , beating expectations by +5.95%.
Earnings released on 5 May 2023
EPS came in at $0.12 surpassing the estimated $0.09 by +33.33%, while revenue for the quarter reached $557.54m , beating expectations by +3.77%.
Earnings released on 2 Mar 2023
EPS came in at $0.23 surpassing the estimated $0.21 by +9.52%, while revenue for the quarter reached $609.76m , beating expectations by +8.47%.
Earnings released on 4 Nov 2022
EPS came in at $0.14 falling short of the estimated $0.18 by -22.22%, while revenue for the quarter reached $545.56m .
Earnings released on 5 Aug 2022
EPS came in at $0.19 falling short of the estimated $0.20 by -5.00%, while revenue for the quarter reached $559.36m .
Earnings released on 4 May 2022
EPS came in at $0.12 matching the estimated $0.12, while revenue for the quarter reached $497.63m , missing expectations by -7.14%.
Earnings released on 2 Mar 2022
EPS came in at $0.18 falling short of the estimated $0.19 by -5.26%, while revenue for the quarter reached $536.90m , beating expectations by +6.89%.
Earnings released on 3 Nov 2021
EPS came in at $0.21 surpassing the estimated $0.20 by +5.00%, while revenue for the quarter reached $528.59m , missing expectations by -2.92%.
Earnings released on 9 Aug 2021
EPS came in at $0.25 surpassing the estimated $0.18 by +38.89%, while revenue for the quarter reached $535.08m , meeting expectations.
AMRX Stock Performance
Access detailed AMRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
